齐博坦在冠状动脉缓慢流动现象中的抗风疗效
Sivabaskari Pasupathy1,2,3, Rosanna Tavella1,2,3, Christopher Zeitz1,2
1School of Medicine, Faculty of Health Sciences, The University of Adelaide, Adelaide, SA 5000, Australia.
Journal of clinical medicine
|April 9, 2024
概括
齐博坦是一种内甲素A受体阻塞剂,在患有耐火性心痛的患者中显著降低了心痛的频率和酸盐的使用. 这为冠状动脉微血管疾病提供了新的治疗选择.
科学领域:
- 心脏病学 心脏病学
- 药理学 药理学是指药理学的学科.
- 血管生物学 血管生物学
背景情况:
- 冠状动脉微血管疾病导致慢性心痛的复发,治疗选择有限.
- 在这些患者中观察到内甲素水平升高.
- 选择性内甲素-A (Et-A) 受体抑制剂,如齐博,是潜在的抗痛疗法.
研究的目的:
- 为了评估zibotentan在因冠状动脉缓慢流动现象而导致耐火性心痛的患者中的疗效.
- 评估一天10毫克的齐博坦坦剂量对自发性心痛发作的影响.
主要方法:
- 随机,双盲,安慰剂控制,交叉试验.随机,双盲,安慰剂控制,交叉试验.
- 18名耐火性心肌痛患者参与了这项研究.
- 主要终点:心痛频率;次要终点:酸盐消耗,心痛严重程度和生活质量 (SAQ).
主要成果:
- 与安慰剂相比,齐博坦坦显著降低了心痛的频率 (p < 0.05).
- 随着齐博坦治疗,口下酸盐消耗显著降低 (p < 0.05).
- 在心痛日记和酸盐使用中观察到改善.
结论:
- 齐博坦有效地改善了对标准治疗无反应的患者的胸痛频率.
- 减少酸盐消耗表明,使用齐博坦可以改善心痛控制.
- 齐博坦在特定患者群体中表现为一种有前途的抗风剂.
相关概念视频
Antianginal Drugs: Calcium Channel Blockers and Ranolazine
498
Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
498
Antianginal Drugs: Nitrates and β-Blockers
579
In cardiovascular health, antianginal drugs combat angina pectoris — a condition marked by chest pain owing to diminished blood flow to the heart.
Organic nitrates, such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow....
Organic nitrates, such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow....
579
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
422
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
422
Antihypertensive Drugs: Vasodilators
516
Vasodilators, primarily affecting the smooth muscles within arterial and venous walls, are commonly used for hypertension treatment. Medications such as minoxidil and hydralazine primarily target arteries and arterioles, while sodium nitroprusside acts on arterioles and venules. Minoxidil, functioning as a prodrug, is metabolized by hepatic sulfotransferase into its active form, minoxidil sulfate, after oral administration. This metabolite binds to the sulfonylurea receptor (SUR) component of...
516
Heart Failure Drugs: β-Blockers
337
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
337
Drug Delivery: Enteral Route
428
The enteral drug administration involves three primary routes: oral, sublingual, and buccal. Oral ingestion is the most prevalent, safe, economical, and convenient method for drug administration. However, it has certain drawbacks, including limited absorption due to the drug's low water solubility or poor membrane permeability, possible emesis from GI mucosa irritation, destruction of drugs by digestive enzymes or low gastric pH, and irregular absorption along with food or other drugs.
428


